| Autor: |
Alexey A. Lugovskoy, Ulrik B. Nielsen, Birgit Schoeberl, Kenneth J. Olivier, Brian D. Harms, Yang Jiao, Maja Razlog, Rachel Rennard, Neeraj Kohli, Lihui Xu, Victoria Rimkunas, Jian Tang, Sergio Iadevaia, Sharlene Adams, Jason Baum, Bryan W. Johnson, Jonathan B. Fitzgerald |
| Rok vydání: |
2023 |
| Popis: |
PDF - 711K, Supplemental Figure S1. Schematic representation of components of IGF-1R/ErbB3 merged mechanistic signaling model. Supplemental Table S1. Mean ligand-stimulated pAKT (S473) levels (A) or simulated levels (B) in BxPC-3, AdRr and MCF7 cells that were used to generate 3D contour plots in Figure 1A. Supplemental Figure S2. Western blots used to generate bar graphs in Figures 1, 3, & 4. Supplemental Figure S3. MM-141 is selective for IGF-1R and ErbB3, and is cross-reactive to relevant toxicology species. Supplemental Table S2. MM-141 is more potent than monospecific antibodies at inhibition of single ligand-induced pAKT (Ser473) signaling. Supplemental Figure S4. MM-141 does not promote basal signaling. Supplemental Figure S5. Generation of isogenic BxPC-3 cell lines with stable knockdown of IGF-1R or ErbB3. Supplemental Table S3. Mean pAKT (S473) levels in engineered BxPC-3 cells that were used to generate 3D contour plots in Figure 3A. Supplemental Figure S6. MM-141 maintains activity over a broad range of receptor profiles. Supplemental Figure S7. Mechanistic model can recapitulate signal inhibition properties of MM-141. Supplemental Figure S8. Pharmacokinetic properties of MM-141. Supplemental Figure S9. MM-141 controls gemcitabine-induced network adaptation. Supplemental Figure S10. MM-141 controls expression of IGF-1R and ErbB3-interacting RTKs. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
